Vortex “As a clinician, I am excited about accessing the cancer biology of patient’s through CTCs. Vortex’s technology provides the best source of CTCs to aid in the diagnostic and treatment decisions we face every day.” – Dr. Jonathan Goldman, MD, Director of Clinical Trials in Thoracic Oncology, Associate Director of Drug Development at UCLA “Improving CTCs recovery along with high cellular purity while maintaining viability have tremendous value for translational research and clinical diagnostic applications. The VTX-1 holds the potential to revolutionize blood-based diagnostics.” - Pr. Massimo Cristofanilli, MD, FACP, Professor of Medicine, Associate Director of Translational Research and Precision Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine Wanda J. Cribbs, Lead Gartner Analyst Population Health & Analytics says: "Wanda's recent HRS press release really stands out. Delivering those results and having a client publicly share credit with their vendor is rare and says a lot. We at Gartner will have our eyes on Wanda in 2018"

Foad Dabiri

CEO of Wanda

Foad Dabiri has been the Chief Technology Officer of Wanda since March 2014, where he has been instrumental in creating Wanda’s unique cloud based platform for the management of chronic disease management and is uniquely placed to lead Wanda as it moves into commercialisation. Before joining Wanda, Foad was a Senior Software Engineer at Google Inc for three years. He has also worked as Principle Scientist at NetSeer Inc. Mr. Dabiri gained a PhD and M.S. in Computer Science at the University of California and, prior to that, was awarded a BS in Electrical Engineering from the Sharif University of Technology.

Foad Dabiri - NetScientific